Vertex Pharmaceuticals (VRTX) valuation against sector peers: P/E 34.9 (sector median 30.7), P/B 6.6, EV/EBIT 31.9, free-cash-flow yield 2.3%, P/S 10.7.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	VRTX	Sector median	vs median
P/E	34.9	30.7 · n=158	14% above
P/B	6.6	4.0 · n=307	66% above
P/S	10.7	4.1 · n=302	163% above
EV/EBIT	31.9	25.8 · n=146	23% above
Free-cash-flow yield	2.3%	1.4% · n=291	63% above
Dividend yield	0.00%	0.00% · n=362	—
Return on equity	20.8%	−2.4% · n=308	—
Return on invested capital	17.6%	0.6% · n=282	2,631% above
Gross margin	85.5%	63.3% · n=205	35% above
Net debt / EBITDA	−0.40	1.27 · n=151	131% below

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Value factor: 55 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	48.9	33.5	—	1.5%	0.6%	6/10
JNJJohnson & Johnson	42.0	8.3	—	3.0%	1.9%	8/10
ABBVAbbVie	50.5	—	27.8	3.6%	2.9%	6/10
MRKMerck	148.8	8.1	—	4.0%	2.3%	8/10
UNHUnitedHealth	22.9	3.5	17.3	6.3%	2.2%	10/10
TMOThermo Fisher Scientific	37.6	4.9	35.6	2.9%	0.3%	9/10
AMGNAmgen	26.8	17.5	23.2	3.8%	2.1%	8/10
GILDGilead Sciences	—	16.3	—	6.5%	1.9%	5/10
ABTAbbott	40.7	3.7	32.9	3.5%	2.8%	6/10
PFEPfizer	41.5	1.9	—	7.0%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 03 Nov 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings